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Background: Multifunctional redox protein human thioredoxin (TRX-1) is reduced by thioredoxin reduc-
tase (TRX-R). The aim of the present study was to examine the distribution of TRX-1 and TRX-R
expressions in gallbladder carcinoma (GBC) to clarify their usefulness as prognostic factors after surgical
resection.
Methods: Immunohistochemical staining for TRX-1 and TRX-R was performed in GBC tissue from 38
patients who underwent surgical resection, and TRX-1/TRX-R localization in relation to outcome was
examined.
Results: TRX-1 protein levels were significantly higher in GBC samples than in cholecystolithiasis
samples (P = 0.0174). TRX-1 expression was observed in 100% (38/38) of tumour samples and in the
nucleus in 76% (29/38), with nuclear expression in the invasion front observed in 45% (13/29). TRX-R
expression was only detected in the cytoplasm of cancer cells and in the invasion front in 28 samples. In
all of the samples, the depth of tumour invasion, lymph node metastasis, surgical margin, curability and
nuclear expression of TRX-1 in the invasion front were significant prognostic factors by univariate
analysis. In 27 selected patients who underwent curative resection, both TRX-1 nuclear expression and
TRX-R cytoplasmic expression in the invasion front was a significantly prognostic factor.
Conclusion: TRX-1 nuclear expression in the GBC invasion front is a significant prognostic marker.
Patients with both TRX-1 nuclear expression and TRX-R cytoplasmic expression in the tumour invasion
front should be observed carefully even if after curative resection.
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Introduction
Gallbladder carcinoma (GBC) is the most frequently occurring of
the biliary cancers.1,2 Resection in numerous cases is impossible
because there are few symptoms, and early diagnosis remains
difficult in spite of recent progress in several diagnostic modali-
ties.2,3 It is generally accepted that the outcome of surgery for GBC
is strongly determined by the depth of tumour invasion (T),
lymph node metastasis (N) and stage.3–7 In addition to these
factors, it is important to clarify the independent molecular bio-
logical markers influencing the prognosis of GBC invading the
subserosal layer or deeper because prognosis of early GBC
restricted to the mucosa or proper muscle layer is comparatively
good.
The cellular redox state is a important mediator of various
metabolic, signalling and transcriptional processes in cells, and a
fine balance between reducing and oxidizing conditions is essen-
tial for the normal function and survival of cells.8,9 Accumulating
evidence indicates that the cellular redox status is involved sub-
stantially in growth promotion and drug resistance of cancer
cells.10,11 Moreover, redox mechanisms play a key role in regulating
the resistance of cancer cells to apoptosis and angiogenesis.12–15
Thioredoxin (TRX) is a multifunctional redox protein found in
both prokaryotic and eukaryotic cells. Human thioredoxin
(TRX-1) is a low-molecular-weight (12 kDa) protein with 27%
amino acid identity to Escherichia coli TRX. TRX was originally
studied because of its ability to act as a reducing co-factor for
ribonucleotide reductase, the first unique step in DNA synthesis
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in E. coli.16 The oxidized TRX is reduced by an NADPH-
dependent thioredoxin reductase (TRX-R), and the reduced TRX
is a very effective protein disulphide reductase. TRX-Rs are the
only enzymes known that can reduce the active site of TRX.
TRX-1 was subsequently shown to exert redox control over a
number of transcription factors including NF-kB, AP-1 and p53,
and indirectly through the nuclear redox protein Redox factor-1.17
TRX modulates the binding of these transcription factors to DNA
and thus regulates gene transcription.
TRX expression is induced by various kinds of oxidative stresses
including viral infection, mitogens, X-ray and UV irradiation,
hydrogen peroxide and post-ischaemic reperfusion.8 Regulation
of the intracellular redox environment is critical for activation and
proliferation of tumour cells.18 Both the overexpression of TRX-1
in various human malignant tumours and the association of
TRX-1 with growth stimulation, anti-apoptosis and angiogenesis
have been reported previously.19,20 Retrospective analyses in col-
orectal carcinoma and non-small cell lung carcinoma have shown
that TRX-1 overexpression may be an independent prognostic
factor of poor survival.21–23
In the present study, to clarify the role of TRX-1 expression in
GBC, we examined both the relation between TRX-1 and TRX-R
expression by immunohistochemical analysis and the prognosis of
patients with GBC.
Table 1 Clinicopathological characteristics in patients with GBC
Variable
Patient background
Gender M : F 17 : 21
Median age (range) 68.5 (40–89)
Tumour factors
Histological type
Pap/tub1/tub2/tub3/other 9/5/12/9/3
Tumour invasion
pT2/ pT3/ pT4 17/3/18
Lymph node metastasis
Negative/positive 17/21
Stage
II/III/IVa/IVb 11/7/8/12
Operative factor
Surgical margin
Negative / positive 31/7
Final curability
fCurA / B / C 14/13/11
GBC, gallbladder cancer.
Table 2 Classification systems for staging, curability by the JSBS
Final stage
H(-), P(-), M(-) H(+), P(+),
M(+)pN0 pN1 pN2 pN3
pT1 I II III IVa IVb
pT2 II III III IVa
pT3 III III IVa IVb
pT4 IVa IVa IVb IVb
Final curability
pN-D Surgical margin
Final curability A, B pN  D And Negative
Final curability C pN > D And/or Positive
JSBS, Japanese Society of Biliary Surgery; H, liver metastasis; P,
metastasis to the peritoneum; M, distant metastasis other than peritoneal
and/or liver metastases; pN, histological lymph node metastasis; D,
lymph node dissection; surgical margin, microscopic surgical margin.
Figure 1 Western blot analysis for TRX-1 protein in tissue samples of
advanced gallbladder carcinoma (GBC) and cholecystolithiasis.
Note the clear bands made by the same antibody used for immu-
nohistochemical analysis. Quantitative analysis indicated that TRX-1
protein level increased significantly by about 2.1-fold in the tissue of
GBC compared with that of cholecystolithiasis (P < 0.05). *Means 
standard deviation of the mean
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Patients and methods
Patients
Thirty-eight patients with GBC except for pT1 cancer restricted to
the mucosa or muscle layer who had undergone surgical resection
from 1990 to 2006 at Miyazaki University Hospital were enrolled
in this study. The patients included 17 men and 21 women with a
median age of 68.5 years (range 40 to 89) (Table 1). The end point
was the evaluation of disease-specific survival after the date of
surgery. The median follow-up time was 34.6 months (range 3.9–
109). Pathological findings of T, N, M, stage and final curability
were classified based on the Japanese Society of Biliary Surgery
classification system24 (Table 2).
The depth of primary tumour invasion (pT) was classified into
the following four groups as: pT1, tumours restricted to the
mucosa or muscle layer; pT2, tumours invading the perimuscular
connective tissue; pT3, tumours perforating the serosa and/or
slightly invading the liver and the hepatoduodenal ligament; and
pT4, tumours extending more than 5 mm into the liver paren-
chyma and/or invading the left margin of the hepatoduodenal
ligament, and/or invading the portal veins or hepatic arteries.
Lymph node metastasis (pN) was classified as: pN0, no regional
lymph node metastasis; pN1, metastasis in the cystic duct and/or
pericholedochal node; pN2, metastasis in the hepatoduodenal
ligament except pN1, posterosuperior pancreas head, along the
common hepatic artery; and pN3, metastasis in the peripancre-
atic, celiac, superior mesenteric and paraaortic lymph nodes. Final
curability (fCur) was classified according to the final histopatho-
logical diagnosis. A curative resection was defined as a complete
removal of the cancer cells with negative histological margins
without the presence of any residual tumour.
All tissue samples were fixed with 10% formalin for immuno-
histochemical investigation and Western blot analysis. Fifteen
Figure 2 Immunohistochemical staining for TRX-1 in advanced gallbladder carcinoma (GBC) and cholecystolithiasis. (a) TRX-1 expression
is revealed by immunohistochemical staining in the cytoplasm of mucosal epithelial cells of cholecystolithiasis. (b) All samples of advanced
GBC showed cytoplasmic expression of TRX-1 in the tumour centre. (c) TRX-1 nuclear expression is confirmed in the invasion front of
advanced GBC. (d) TRX-1 nuclear expression is confirmed in the tumour centre of advanced GBC
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Figure 3 Survival curves of the four groups of patients with advanced gallbladder carcinoma (GBC) after surgical resection according to the
presence or absence of TRX-1 nuclear expression and location are shown. There is a significant difference in survival between the patients
with TRX-1 nuclear expression only in the invasion front and the patients with TRX-1 nuclear expression only in the tumour centre (P < 0.05)
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Figure 4 Survival curves of the patients with advanced gallbladder carcinoma (GBC) after surgical resection according to the location of
TRX-1 nuclear expression of GBC are shown. The post-operative survival rate of the patients with TRX-1 nuclear expression in the invasion
front of GBC (n = 13) was significantly worse than that of the patients with TRX-1 nuclear expression only in the tumour centre (n = 16)
(P = 0.0387)
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samples from patients with cholecystolithiasis who had under-
gone a cholecystectomy were used as normal controls.
The present study was conducted according to the ethical prin-
ciples stated in the latest version of the Helsinki Declaration and
the applicable guidelines for good clinical practice. The experi-
mental design in this study was approved by the ethics committee
of Miyazaki University Hospital, article no. 763.
Western blot analysis of TRX-1
Western blot analysis was performed as previously described.25
Tissues taken from GBC and cholecystolithiasis specimens were
homogenized in protein lysis buffer. After centrifugation of the
crude homogenate, protein concentration was measured. Samples
containing 10 mg of protein were applied/lane to gel, and the gel
was electrophoresed. Proteins were transferred electrophoretically
onto membranes. The blotted membranes were incubated with
monoclonal antibodies against human TRX-1 (Redox Bio Science,
Kyoto, Japan) (1 : 2500) for 16 h at 4°C. The membranes were
incubated with anti-mouse secondary antibody conjugated to
mouse peroxidase for 1 h at room temperature. ECL Plus was used
to detect the proteins, and the luminol excitation was imaged.
b-Actin expression was detected with the same membranes after
stripping them of bound antibodies. Detection and imaging were
performed as described for TRX-1.26,27
Immunohistochemical analysis for TRX-1 and TRX-R
Formalin-fixed paraffin-embedded tumour sections were
mounted on glass slides, dewaxed with xylene and then trans-
ferred to alcohol. To enhance immunoreactivity of TRX-1, we
retrieved antigens by autoclaving at 121 °C for 12 min in citrate
buffer (pH = 6.0). The primary antibodies used were TRX-1
monoclonal antibody (Redox Bio Science, Kyoto, Japan; dilution
1 : 500).21,22 The appearance of TRX-1 was confirmed with the
dyed specimen, and the expression pattern was determined.
TRX-R expression was analysed similarly with TRX-R 2 poly-
clonal antibody.26
Statistical analysis
The difference in clinicopathological factors between patients
with and without TRX-1 nuclear expression was examined using
Fisher’s exact text. Survival rates were calculated by the Kaplan–
Meier method, and statistical differences were examined by the
log-rank test. Probability values of <0.05 were considered statisti-
cally significant. Analyses were performed with JMP for Macin-
tosh (SAS Institute, Cary, NC, USA).
Results
Western blot analysis for TRX-1
The specificity of TRX-1 antibody in GBC was determined by
Western blot analysis. A clear single TRX-1 protein band was
shown at the molecular weight of approximately 12 kDa, and
TRX-1 protein levels of GBC samples were significantly higher
than those of samples of cholecystolithiasis (P = 0.0174) (Fig. 1).
Immunohistochemical analysis for TRX-1
TRX-1 was detected in 8 of 15 samples of cholecystolithiasis (53%
positivity rate), with staining located mainly in the cytoplasm of
mucosal epithelial cells (Fig. 2a). In contrast, TRX-1 expression
was confirmed in all samples of GBC (100% positivity rate).
TRX-1 expression in the cytoplasm of the cancer cells was
Table 3 Clinicopathological factors of patients with and without
TRX-1 nuclear expression in the invasion front
Variable No. of
patients
TRX-1 nuclear
expression
in the
invasion front
P-value
Absence Presence
Gender 0.897
M 13 7 6
F 16 9 7
Age (years) 0.5335
<65 13 8 5
65 16 8 8
Histological
type (pap+tub1
vs. tub2,3)
0.3754
pap 8 5 3
tub1 4 3 1
tub2 10 4 6
tub3 6 4 2
Tumour
invasion
(pT2 vs. pT3, 4)
0.5335
pT2 13 8 5
pT3 3 1 2
pT4 13 7 6
Lymph node
metastasis
0.6381
Negative 12 6 6
Positive 17 10 7
Stage (Stage II
vs. III, IV)
0.2373
II 8 3 5
III 6 5 1
Iva 5 5 0
IVb 10 3 7
Final curability 0.4364
fCurA, B 20 12 8
fCurC 9 4 5
TRX, thioredoxin.
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observed in all samples (Fig. 2b). TRX-1 nuclear expression was
confirmed in 29 of the 38 samples of GBC (76%), not in the entire
tumour but in a part of the tumour. The invasion front was
defined as the deepest cancerous lesion infiltrated. TRX-1 nuclear
expression only in the invasion front of the tumour was confirmed
in four samples (Fig. 2c), in both the invasion front and the
tumour centre in 9 samples, and only in the tumour centre in 16
samples (Fig. 2d). Thus, TRX-1 nuclear expression in the invasion
front was observed in 13 of the 29 samples.
Relation between the localization of TRX-1nuclear
expression and outcome
There were no statistically significant differences in clinicopatho-
logical characteristics between the patients with TRX-1 nuclear
expression only in the invasion front (n = 4) and those with TRX-1
nuclear expression in both the invasion front and tumour centre
(n = 9). Prognosis of these 13 patients with TRX-1 nuclear expres-
sion in the invasion front was poor, and none of these patients
survived for more than 5 years (Fig. 3). Patient outcome was sig-
nificantly poorer (P = 0.0387) in patients with TRX-1 nuclear
expression observed in the invasion front (n = 13) than in patients
with TRX-1 nuclear expression observed only in the tumour
centre (n = 16) (Fig. 4). Differences in clinicopathological factors
and curability (presence or absence of the residual tumour) are
shown in Table 3. There were no statistically significant differences
between the two groups.
TRX-R expression
TRX-R expression in GBC was confirmed in 36 of the 38 samples.
TRX-R was expressed in the cytoplasm of the cancer cells, whereas
its nuclear expression was not observed. TRX-R cytoplasmic
expression was confirmed only in the invasion front in four
samples, in both the invasion front and the tumour centre in 24
samples and only in the tumour centre in 8 samples. Thus, TRX-R
cytoplasmic expression in the invasion front was confirmed in 28
of the 38 samples. No significant difference in post-operative sur-
vival rate was observed between patients with and without TRX-R
expression in the invasion front (P = 0.986) (Fig. 5).
Prognostic factors of GBC
Clinicopathological characteristics of GBC that can predict a poor
prognosis were identified (Table 4). Univariate analysis showed
that depth of tumour invasion, lymph node metastasis, surgical
margin and curability were all significant prognostic factors.
Similarly, the presence of TRX-1 nuclear expression in the inva-
sion front was also a significant prognostic factor by univariate
analysis.
As curability as an operative factor was a significant prognostic
factor, prognostic factors in selected 27 patients who underwent
curative resection (fCurA, B) were examined. Post-operative sur-
vival was significantly worse in the patients with the presence of
both TRX-1 nuclear expression and TRX-R cytoplasmic expres-
sion in the invasion front than in those without this expression
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Figure 5 Survival curves of the patients with advanced gallbladder carcinoma (GBC) after surgical resection according to the presence or
absence of TRX-R expression in the invasion front of GBC are shown. There was no significant difference in post-operative survival rates
between the patients with and without the presence of TRX-R expression
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Table 4 Clinicopathological factors influencing post-operative sur-
vival in patients with GBC
Variable No. of
patients
3-year
survival
rate (%)
5-year
survival
rate (%)
P-value
Patient background
Gender
M 17 35 29 0.4888
F 21 48 43
Age (years)
<65 14 29 29 0.5182
65 24 53 43
Tumour factors
Histological type
pap, tub1 14 55 47 0.0787
tub2, tub3 21 31 26
Tumour invasion
pT2 17 69 63 0.0050
pT3, pT4 21 26 16
Lymph node
metastasis
Negative 17 63 56 0.0248
Positive 21 26 21
Stage (Stage II
vs. III–IV)
II 11 70 60 0.0616
III 7 57 57
Iva 8 45 45
IVb 12 8 0
TRX-1 nuclear
expression in
the invasion front
Absence 25 55 51 0.0391
Presence 13 17 0
TRX-R cytoplasmic
expression in the
invasion front
Negative 10 35 35 0.9859
Positive 28 45 37
TRX-1 nuclear and
TRX-R cytoplasmic
expression in
the invasion front
Absence 28 53 49 0.0257
Presence 10 11 0
Operative factor
Surgical margin
Negative 31 49 46 0.0362
Positive 7 14 0
Final curability
fCurA, B 27 57 53 0.0013
fCurC 11 9 0
GBC, gallbladder cancer; TRX, thioredoxin; TRX-R, thioredoxin reduc-
tase; surgical margin, microscopic surgical margin.
Table 5 Clinicopathological factors influencing post-operative sur-
vival in patients with GBC after curative resection
Variable No. of
patients
3-year
survival
rate (%)
5-year
survival
rate (%)
P-value
Patient background
Gender
M 9 61 61 0.5827
F 18 55 50
Age (years)
<65 10 40 40 0.3546
65 17 70 63
Tumour factors
Histological type
pap, tub1 10 80 69 0.1322
tub2, tub3 15 36 36
Tumour invasion
pT2 17 69 63 0.1650
pT3, pT4 10 36 36
Lymph node
metastasis
Negative 15 72 65 0.1432
Positive 12 39 39
Stage (Stage II
vs III-IV)
II 11 70 60 0.3974
III 7 57 57
Iva 6 62 62
IVb 3 0 0
TRX-1 nuclear
expression in
the invasion front
Absence 19 68 68 0.0465
Presence 8 29 0
TRX-R cytoplasmic
expression in
the invasion front
Negative 7 51 51 0.7938
Positive 20 58 53
TRX-1 nuclear
and TRX-R
cytoplasmic
expression in the
invasion front
Absence 21 66 66 0.0117
Presence 6 21 0
GBC, gallbladder cancer; TRX, thioredoxin; TRX-R, thioredoxin
reductase.
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(P < 0.012, Table 5). There were no statistically significant
differences in several clinicopathological factors including the
depth of tumour, lymph node metastasis and stage between these
two groups (data not shown). The presence of TRX-1 nuclear
expression in the invasion front significantly worsened the
outcome (Table 5).
Discussion
Recently, several reports have been published concerning factors
predictive of poor prognosis in GBC, such as p53 and COX-2.28,29
It is important to predict the post-operative prognosis of GBC so
that the appropriate patients can be recommended for combined
adjuvant therapy. The results of the present study suggest that
nuclear expression of TRX-1 in the tumour invasion front may be
a significant prognostic marker of survival in patients with GBC.
In the present study, we first analysed the mode and localization
of TRX-1 expression in GBC. Previous studies have reported the
overexpression of TRX-1 in various malignant tumours such as
malignant melanoma and lung and breast carcinoma.26,27,30–33
Yoon et al. also reported TRX overexpression in cholangiocarci-
noma by Western blot analysis.34 The present study indicated that
TRX-1 was overexpressed in all of the cases of GBC.
TRX-1 expression was detected in the cytoplasm in all GBC
samples, whereas nuclear expression was confirmed in 76% of
samples. The extent of TRX-1 nuclear expression differed depend-
ing on its location in the tumour, whether in the invasion front of
the tumour, in the tumour tissues, or in both. In previous studies,
it was reported that TRX-1 mainly appears in the cytoplasm, and
its expression was also seen in the nuclei of colorectal and lung
carcinomas.21–23 In breast cancer, cytoplasmic staining for TRX-1
has been reported to vary between 48% and 67%, and nuclear
staining varies between 59% and 63%.33,35
In the present study, TRX-1 nuclear expression in the invasion
front was a significant prognostic factor in GBC. In the cytoplasm,
TRX-1 works as an antioxidant and a reducing cofactor, whereas
in the nucleus, it regulates transcription factors, and this is prob-
ably the most important role of TRX-1. TRX activity has also been
detected in the extracellular space, and it stimulates cell growth by
sensitizing the cell itself.18 TRX-1 has also been shown to translo-
cate into the nuclei of normal endothelial and tumour cells, and
treatments with H2O2, hypoxia, nitric oxide, ionizing radiation
and anticancer drugs such as cisplatin, for example, further
increase this translocation.36–40 It has been suggested that the
translocation of TRX-1 into the nucleus strongly correlates with
p53 expression and a poor prognosis in breast cancer.33 Moreover,
it was reported that TRX-1 expression relates to poor prognosis of
lung cancer and liver metastasis from colorectal cancer.22,23
In the present study, it was shown that the prognosis of the
patients with the presence of TRX-1 nuclear expression in the
invasion front was significantly worse compared with its absence.
Jung et al. reported that the oncogene b-catenin is found in the
nuclear compartment of tumour cells in the invasion front of
well-differentiated colorectal adenocarcinomas.41 Under these
conditions, b-catenin can function as a transcription factor and
thus activate target genes. One of these target genes, cyclin D1, is
known to reduce tumour cell proliferation. It is suggested that
translocation of TRX-1 in the invasion front into the nucleus
invests high infiltration and/or metastatic capability to the cancer
cell. However, the details of the mechanisms of TRX-1 nuclear
expression associated with poor prognosis require further study.
Prognosis of GBC remains poor even in patients after curative
surgical resection. In the present study, the presence of both
TRX-1 nuclear expression and TRX-R cytoplasmic expression in
the invasion front was a prognostic factor for survival after cura-
tive resection. TRX-1 nuclear expression in the invasion front may
be a useful prognostic marker of GBC. In addition, we propose
that patients with both TRX-1 nuclear expression and TRX-R
cytoplasmic expression in the invasion front of the tumour should
be treated with adjuvant therapy even if after curative resection.
Recently, it was reported that cisplatin plus gemcitabine is an
appropriate option for the treatment of patients with advanced
biliary cancer.42
More extensive studies will be required to determine whether
TRX-1 nuclear expression can be used reliably as a prognostic
marker for GBC. TRX-1 inhibitors are being developed as anti-
cancer agents to stimulate spontaneous and drug-induced apop-
tosis and to inhibit tumour growth.43–46 Therefore, in patients with
GBC in which TRX-1 is overexpressed, TRX-1 inhibitors may be a
promising treatment for GBC.
Conclusions
TRX-1 nuclear expression in the tumour invasion front of patients
with GBC may be a useful prognostic marker for survival. We
propose that patients with both TRX-1 nuclear expression and
TRX-R cytoplasmic expression in the invasion front of the
tumour should be observed carefully even if after curative surgical
resection.Additional studies including a larger number of patients
need to be done to confirm the clinical significance of thioredoxin.
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